This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sally J. Boyson, MD
Department of Neurology University of Colorado Health Sciences Center 4200 E Ninth Ave Denver, CO 80262

Arch Neurol. 1991;48(9):902.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The exciting news that selegiline (deprenyl, Eldepryl) may retard the progression of early Parkinson's disease,^1,2 accompanied by the observation that few significant adverse effects were observed in these studies, has led physicians to treat many of their Parkinson's disease patients with this drug. This report concerns adverse psychiatric effects seen in my referral population of patients with Parkinson's disease. Over the last year, we have started selegiline therapy in approximately 60 patients, almost all of whom were both on multiple other antiparkinsonian medications and known to me for some time prior to this treatment. I have not included adverse effects that could be ameliorated by reduction of the dose of carbidopa/levodopa.

Apparent adverse effects in the younger population were most common in physically small patients, especially women. Five otherwise healthy women in their 40s and 50s developed adverse effects, although only two of these had a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?